The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer
Open accessAbstract
BACKGROUND: Preclinical data support further investigation of ascorbic acid in pancreatic cancer. There are currently insufficient safety data in human subjects, particularly when ascorbic acid is combined with chemotherapy. METHODS AND FINDINGS: 14 subjects with metastatic stage IV pancreatic cancer were recruited to receive an eight week cycle of intravenous ascorbic acid (three infusions per week), using a dose escalation design, along with standard treatment of gemcitabine and erlotinib. Of 14 recruited subjects enrolled, nine completed the study (three in each dosage tier). There were fifteen non-serious adverse events and eight serious adverse events, all likely related to progression of disease or treatment with gemcitabine or erlotinib. Applying RECIST 1.0 criteria, seven of the nine subjects had stable disease while the other two had progressive disease. CONCLUSIONS: These initial safety data do not reveal increased toxicity with the addition of ascorbic acid to gemcitabine and erlotinib in pancreatic cancer patients. This, combined with the observed response to treatment, suggests the need for a phase II study of longer duration. TRIAL REGISTRATION: Clinicaltrials.gov NCT00954525.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · Trials · doi:10.1186/1745-6215-11-32 · Cited by 1,871
Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance
Levine, M., Conry-Cantilena, C., Wang, Y., Welch, R. W., Washko, P. W., Dhariwal, K. R., Park, J. B., Lazarev, A., Graumlich, J. F., King, J., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3704 · Cited by 1,325
Self-citationChen, Q., Espey, M. G., Krishna, M. C., Mitchell, J. B., Corpe, C. P., Buettner, G. R., Shacter, E., & Levine, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506390102 · Cited by 1,075
Self-citationChen, Q., Espey, M. G., Sun, A. Y., Pooput, C., Kirk, K. L., Krishna, M. C., Khosh, D. B., Drisko, J., & Levine, M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804226105 · Cited by 854
Self-citationMoertel, C. G., Fleming, T. R., Creagan, E. T., Rubin, J., O'Connell, M. J., & Ames, M. M. (1985) · New England Journal of Medicine · doi:10.1056/nejm198501173120301 · Cited by 637
Creagan, E. T., Moertel, C. G., O'Fallon, J. R., Schutt, A. J., O'Connell, M. J., Rubin, J., & Frytak, S. (1979) · New England Journal of Medicine · doi:10.1056/nejm197909273011303 · Cited by 584
A new recommended dietary allowance of vitamin C for healthy young women
Levine, M., Wang, Y., Padayatty, S. J., & Morrow, J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171318198 · Cited by 496
Research works printed but not linked: 22
- CJ Yeo, 1997, Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes., Ann Surg, 226, 248, 10.1097/00000658-199709000-00004 · DOI · Paper page
- E Van Cutsem, 2004, Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer., J Clin Oncol, 22, 1430, 10.1200/JCO.2004.10.112 · DOI · Paper page
- M Reni, 2005, Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: A randomized controlled multicentre phase III trial., Lancet Oncol, 6, 369, 10.1016/S1470-2045(05)70175-3 · DOI · Paper page
- E Cameron, 1976, Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer., Proc Natl Acad Sci U S A, 73, 3685, 10.1073/pnas.73.10.3685 · DOI · Paper page
- RE Wittes, 1985, Vitamin C and cancer., N Engl J Med, 312, 178, 10.1056/NEJM198501173120310 · DOI
- ID Coulter, 2006, Antioxidants vitamin C and vitamin E for the prevention and treatment of cancer., J Gen Intern Med, 21, 735, 10.1111/j.1525-1497.2006.00483.x · DOI
- SJ Padayatty, 2000, Reevaluation of ascorbate in cancer treatment: emerging evidence, open minds and serendipity., J Am Coll Nutr, 19, 423, 10.1080/07315724.2000.10718941 · DOI
- SJ Padayatty, 2004, Vitamin C pharmacokinetics: Implications for oral and intravenous use., Ann Intern Med, 140, 533, 10.7326/0003-4819-140-7-200404060-00010 · DOI · Paper page
- LJ Hoffer, 2008, Phase I clinical trial of i.v. ascorbic acid in advanced malignancy., Ann Oncol, 19, 1969, 10.1093/annonc/mdn377 · DOI · Paper page
- Q Chen, 2007, Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo., Proc Natl Acad Sci U S A, 104, 8749, 10.1073/pnas.0702854104 · DOI · Paper page
- MG Espey, 2011, Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer., Free Radic Biol Med, 50, 1610, 10.1016/j.freeradbiomed.2011.03.007 · DOI · Paper page
- P Jackson, 1995, Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure., Clin Chem, 41, 1135, 10.1093/clinchem/41.8.1135 · DOI · Paper page
- W Shaib, 2010, Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients., Anticancer Res, 30, 4261
- J Feliu, 2011, Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer., Cancer Chemother Pharmacol, 67, 215, 10.1007/s00280-010-1472-0 · doi:10.1007/s00280-010-1472-0
- D Cunningham, 2009, Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer., J Clin Oncol, 27, 5513, 10.1200/JCO.2009.24.2446 · DOI · Paper page
- A Ardavanis, 2009, Biweekly gemcitabine (GEM) in combination with erlotinib (ERL): an active and convenient regimen for advanced pancreatic cancer., Anticancer Res, 29, 5211
- V Heinemann, 2006, Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer., J Clin Oncol, 24, 3946, 10.1200/JCO.2005.05.1490 · DOI · Paper page
- GP Stathopoulos, 2006, A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first line treatment in patients with locally advanced or metastatic pancreatic cancer., Br J Cancer, 95, 587, 10.1038/sj.bjc.6603301 · DOI · Paper page
- HA Burris 3rd, 1997, Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial., J Clin Oncol, 15, 2403, 10.1200/JCO.1997.15.6.2403 · DOI · Paper page
- JA Drisko, 2003, The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer., J Amer Coll Nutr, 22, 118, 10.1080/07315724.2003.10719284 · DOI
- SJ Padayatty, 2006, Intravenous vitamin C as cancer treatment: Three cases., Can Med Assoc J, 174, 937, 10.1503/cmaj.050346 · DOI · Paper page
- MJ Moore, 2007, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group., J Clin Oncol, 25, 1960, 10.1200/JCO.2006.07.9525 · DOI · Paper page
Cited by
ROS and the DNA damage response in cancer
Srinivas, U. S., Tan, B. W. Q., Vellayappan, B. A., & Jeyasekharan, A. D. (2019) · Redox Biology · doi:10.1016/j.redox.2018.101084 · Cited by 2,144
Ascorbic acid: Chemistry, biology and the treatment of cancer
Du, J., Cullen, J. J., & Buettner, G. R. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.06.003 · Cited by 1,070
Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH
Yun, J., Mullarky, E., Lu, C., Bosch, K. N., Kavalier, A., Rivera, K., Roper, J., Chio, I. I. C., Giannopoulou, E. G., Rago, C., et al. (2015) · Science · doi:10.1126/science.aaa5004 · Cited by 913
Ma, Y., Chapman, J., Levine, M., Polireddy, K., Drisko, J., & Chen, Q. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007154 · Cited by 501
Self-citationSchoenfeld, J. D., Sibenaller, Z. A., Mapuskar, K. A., Wagner, B. A., Cramer-Morales, K. L., Furqan, M., Sandhu, S., Carlisle, T. L., Smith, M. C., Abu Hejleh, T., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.018 · Cited by 443
Metadata
- Authors
- Monti, D. A., Mitchell, E., Bazzan, A. J., Littman, S., Zabrecky, G., Yeo, C. J., Pillai, M. V., Newberg, A. B., Deshmukh, S., & Levine, M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-01-17
- Volume
- 7
- Issue
- 1
- Pages
- e29794
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2076098030
- Cited by
- 274
- References
- 13
- FWCI
- 9.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer. https://app.cochat.ai/papers/10.1371/journal.pone.0029794
- The paper
- Monti, D. A., Mitchell, E., Bazzan, A. J., Littman, S., Zabrecky, G., Yeo, C. J., Pillai, M. V., Newberg, A. B., Deshmukh, S., & Levine, M. (2012). Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer. PLoS ONE. https://doi.org/10.1371/journal.pone.0029794
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
